The Dutch Prolactinoma Cohort Studies: Cross-sectional Analysis of Females Focusing on the Patient's Perspective

Clicks: 4
ID: 324852
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #79 of 360 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 360 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose To assess the results of patient-reported outcome measures (PROMs) in a national cohort of females with a prolactinoma by disease activity. Methods Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal (ULN)) and controlled (prolactin<ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease (LBNQ-Pituitary)). Results Four hundred and fifty females with a prolactinoma were included (active: n=223, controlled: n=227), most were treated with dopamine agonists (DAs) (97.0%). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 p<0.001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 p<0.001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9 (p<0.001). Conclusions Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue, psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
Reference Key
openalex_W7202348841 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Victoria R. van Trigt, Iris C. M. Pelsma, Ingrid M. Zandbergen, Leontine E H Bakker, Olaf M. Dekkers, Amir H. Zamanipoor Najafabadi, Saskia le Cessie, M. Elske van den Akker‐van Marle, Madeleine L. Drent, Dirk Jan Stenvers, Ingrid I L Berk-Planken, Kees van den Berge, M Andĕl, Kitty Kapiteijn, Sanne G H A Swinnen, Aline M E Stades, Richard A. Feelders, Annenienke C. van de Ven, Jantien Hoogmoed, Melanie M. van der Klauw, Alberto M. Pereira, Cornelie D. Andela, Marco J. T. Verstegen, Wouter R. van Furth, Nienke R. Biermasz
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag331
URL
https://doi.org/10.1210/clinem/dgag331
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.